Internal Medicine, Hematology & Oncology · Columbia, MO
NPI
1497723472
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1705 E Broadway, Suite 100
Columbia, MO, 65201
Phone (573) 874-7800
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.1M
194,394 services
Medicare patients, 2024
926
Average age 75
Drug cost, 2024
$5.2M
1,919 prescriptions
Company payments, 2025
$2,946
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark M Tungesvik was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 35,200 times for 48 patients. In total Mark M Tungesvik billed 194,394 services in 159 codes, and Medicare paid $3.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-28.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 35,200 | 48 | $2.31 | $81K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,000 | 37 | $44.83 | $807K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 16,100 | 152 | $0.10 | $1,679 |
| J0185 Injection, aprepitant, 1 mg | Office | 11,830 | 42 | $1.30 | $15K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 8,100 | 13 | $0.05 | $425 |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,727 | 24 | $0.08 | $619 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 5,940 | 11 | $39.27 | $233K |
| J0897 Injection, denosumab, 1 mg | Office | 4,200 | 45 | $19.71 | $83K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,600 | 23 | $15.75 | $41K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,280 | 18 | $36.78 | $84K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,024 | 92 | $0.09 | $178 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 1,980 | 12 | $21.25 | $42K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,291 | 59 | $0.69 | $887 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,020 | 48 | $0.25 | $258 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 838 | 18 | $3.37 | $2,821 |
By year: 2022 $4.3M for 398,584 services; 2023 $4.7M for 328,665 services; 2024 $3.1M for 194,394 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark M Tungesvik prescribed most often to Medicare patients was Anastrozole, with 228 prescriptions and refills. In total Mark M Tungesvik wrote 1,919 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 228 | 537 | 61 | $3,792 |
| Hydroxyurea Generic | 113 | 204 | 20 | $2,833 |
| Gabapentin Generic | 111 | 157 | 28 | $1,451 |
| Fentanyl Generic | 97 | 97 | 27 | $7,766 |
| Oxycodone Hcl Generic | 95 | 95 | 31 | $1,388 |
| Prochlorperazine Maleate Generic | 67 | 68 | 39 | $889 |
| Tamoxifen Citrate Generic | 67 | 144 | 20 | $1,528 |
| Revlimid Lenalidomide | 65 | 65 | 14 | $1.1M |
| Prednisone Generic | 55 | 63 | 19 | $317 |
| Eliquis Apixaban | 54 | 66 | Under 11 | $44K |
| Dexamethasone Generic | 48 | 49 | 29 | $910 |
| Famotidine Generic | 45 | 55 | 13 | $137 |
| Acyclovir Generic | 44 | 60 | Under 11 | $688 |
| Potassium Chloride Generic | 41 | 61 | 13 | $746 |
| Omeprazole Generic | 35 | 43 | Under 11 | $211 |
Brand drugs: - claims; generic drugs: 1,487 claims; opioid claims: 245.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark M Tungesvik $2,946 ($2,946 in general payments such as food, travel and fees) from 27 companies. The largest payer was Abbvie Inc. with $309.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 14 | $309 |
| Daiichi Sankyo Inc. 4568.T | 9 | $301 |
| E.R. Squibb & Sons, L.L.C. BMY | 17 | $286 |
| Pfizer Inc. PFE | 16 | $209 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $198 |
| Merck Sharp & Dohme LLC MRK | 10 | $186 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $174 |
| Gilead Sciences, Inc. GILD | 5 | $155 |
| Celgene Corporation BMY | 11 | $152 |
| GlaxoSmithKline, LLC. GSK | 6 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.